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ABSTRACT
A recent phase III trial comparing granulocyte colony-stimulating factor (G-CSF)–stimulated bone marrow
(G-BM) and G-CSF–mobilized peripheral blood (G-PB) in matched sibling allograft recipients showed that
G-BM produced a similar hematologic recovery but a reduced incidence of extensive chronic graft-versus-host
disease, indicating differences in the cell populations infused. As a first step toward identifying these differ-
ences, we treated a group of healthy adult humans with 4 daily doses of G-CSF 10 g/kg and monitored the
effects on various hematopoietic and immune cell types in the PB and BM over 12 days. G-CSF treatment
caused rapid and large but transient increases in the number of circulating CD34 cells, colony-forming cells,
and long-term culture-initiating cells and in the short-term repopulating activity detectable in nonobese
diabetic/severe combined immunodeficiency/2-microglobulin–null mice. Similar but generally less marked
changes occurred in the same cell populations in the BM. G-CSF also caused transient perturbations in some
immune cell types in both PB and BM: these included a greater increase in the frequency of naive B cells and
CD123 dendritic cells in the BM. The rapidity of the effects of G-CSF on the early progenitor activity of the
BM provides a rationale for the apparent equivalence in rates of hematologic recovery obtained with G-BM and
G-PB allotransplants. Accompanying effects on immune cell populations are consistent with a greater ability
of G-BM to promote tolerance in allogeneic recipients, and this could contribute to a lower rate of chronic
graft-versus-host disease.
© 2004 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
The safety and ease of procuring granulocyte
olony-stimulating factor (G-CSF)–mobilized pe-
ipheral blood (G-PB) cells from healthy donors
nd the faster engraftment obtained in allogeneic
ecipients of these cells as compared with normal
teady-state bone marrow (BM) cells are now widely
ecognized [1–4]. In addition, 2 randomized trials
omparing transplants of allogeneic G-PB and i
24teady-state BM have demonstrated a beneﬁt to the
ecipients of G-PB cells in both overall [3] and
isease-free [1] survival. In contrast, the related
uestion of whether allogeneic G-PB transplants
re associated with a signiﬁcantly higher incidence
r severity of acute or chronic graft-versus-host
isease (GVHD) has not yet been resolved [5–8]. A
eta-analysis demonstrated a small but signiﬁcantncrease in both acute and chronic GVHD in recip-
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G-CSF Effects on Marrow and Peripheral Blood Cells
Bents of G-PB [9]. Whether this compromises qual-
ty of life or survival is not known. Recently, a
umber of groups have evaluated the use of alloge-
eic BM transplants obtained from G-CSF–stimu-
ated healthy donors [10–13]. These studies have
stablished the safety of using this source of cells
nd the ability of G-CSF–stimulated bone marrow
G-BM) to produce rapid and sustained engraft-
ent. A small, randomized phase III trial compar-
ng matched sibling G-BM with G-PB allografts
ndicated comparable rates of hematologic recovery
nd a signiﬁcant reduction in the incidence of both
verall (47% versus 90%; P  .02) and extensive
hronic (22% versus 80%; P  .002) GVHD in
-BM recipients, although the incidence of chronic
VHD in the G-PB population was high [14].
Taken together, these studies have suggested
hat G-CSF may differentially modulate the BM
nd PB content of the immune cells responsible for
VHD while causing similar effects on the cells
esponsible for hematologic recovery. G-PB con-
ains more T cells than does steady-state BM, al-
hough the relationship between the number of
D4 T cells infused and the incidence of GVHD
n patients receiving G-PB is uncertain. Evaluation
f the dendritic cell (DC) populations in G-PB has
ndicated that an increased number of plasmacytoid
Cs or interferon (IFN)–producing DCs is associ-
ted with induction of a T-helper type 2–type re-
ponse and induction of tolerance [15,16]. The
umber of CD34 cells infused has also been asso-
iated with the rate of onset of GVHD in patients
eceiving G-PB [17]. This has suggested that im-
ature CD34 myeloid-lineage DCs may play a
igniﬁcant role in the development of GVHD in
ecipients of G-PB transplants. More recently, G-
SF treatment was shown to produce an increase in
xpression of GATA-3 [18], an important transcrip-
ion factor in the induction of T-helper type 2 T
ells and their secretion of interleukin (IL)–4.
owever, relatively little is known about the effects
hat G-CSF administration may have on immune
ell populations that are released into the PB as
ompared with those that remain in the BM. Simi-
arly, whereas the ability of G-CSF treatment to
ncrease the concentration of primitive hematopoi-
tic progenitor cells in the blood is well established
19–22], only a few studies have investigated the
ffects of G-CSF on the progenitor activity of hu-
an BM [23–26].
This study was designed to obtain quantitative
omparative data on the effects of a 4-day course of
-CSF on various phenotypically and functionally
eﬁned populations of cells with immune and hema-
opoietic activities in the PB and BM of healthy indi-
iduals followed up serially over 12 days. n
B&MTETHODS
olunteer Selection, G-CSF Treatment and
ample Collection, Distribution, and Cell
reparation
Ten healthy volunteers between 18 and 30 years of
ge were recruited at the Halifax site after informed
onsent was obtained under the aegis of an institu-
ionally approved protocol. Exclusion criteria were
ny of the following: medical comorbidities (speciﬁ-
ally, cardiopulmonary disease, autoimmune disease,
hronic skin conditions, or obesity), pregnancy or lac-
ation, splenomegaly, known allergy to lidocaine,
nown hypersensitivity to Escherichia coli–derived
roducts, or abnormalities on screening complete
lood count or liver enzymes. Volunteers received
-CSF 10 g/kg subcutaneously once daily for 4
onsecutive days (days 0, 1, 2, and 3). All volunteers
ere followed up to 90 days after G-CSF administra-
ion, and no adverse reactions were noted.
Heparinized PB and BM aspirate samples were
btained before, during, and up to 12 days after the
rst injection of G-CSF. All BM aspirates were per-
ormed by 2 individuals (S.C. and L.R.S.) by using a
tandard technique: 2 mL of BM was aspirated in a
ingle draw and placed immediately in a tube. An
liquot of each PB and BM sample was analyzed on
he day of collection in Halifax to determine the con-
entration of total nucleated cells (TNCs), with an
utomated cell counter, and the concentration of
D34 cells and colony-forming cells (CFCs) after
ysis of the red blood cells, as described below. Addi-
ional aliquots were sent by overnight courier to Van-
ouver for immune cell analyses, long-term culture–
nitiating cell (LTC-IC) assays, measurement of
hort-term repopulating cell (STRC) activity in im-
unodeﬁcient mice, and repeat CFC assays on
D34 cell-enriched populations. The latter were
solated immunomagnetically from low-density PB
nd untreated BM cells using the EasySep procedure
StemCell Technologies, Vancouver, BC, Canada). In
few cases, PB or BM cells were ﬁrst cryopreserved in
0% dimethyl sulfoxide and 90% fetal calf serum. In
hese cases, progenitor values measured on the thawed
amples were corrected by the estimated losses in-
urred from the freezing and thawing. These were
stimated by comparing the differences in CFC values
easured in Halifax (before freezing) and subse-
uently after thawing in Vancouver for the same num-
er of prefreezing cells.
henotyping Studies
Flow cytometric determinations of BM CD34
ell counts were undertaken in Halifax as recom-
ended by the International Society for Cellular
herapy [27] by using CD45–ﬂuorescein isothiocya-
ate (FITC) and CD34-phycoerythrin (PE) monoclo-
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6al antibodies from StemKit (Beckman Coulter, Mi-
mi, FL). The same method was used for PB CD34
ell enumeration after correction of the white blood
ell count for the presence of nucleated erythroid
ells.
Phenotype analyses of immune cells were per-
ormed in Vancouver on whole blood by using the
ollowing monoclonal antibodies: CD4-CyC, CD8-
E, T-cell receptor (TCR)–FITC, CD45RO–an-
igen-presenting cell (APC), CD45RA-CyC, CD123-
E, CD11c-APC, lin-FITC, HLA-DR-PerCP,
D33-FITC, CD19-CyC, immunoglobulin D–PE,
D25-CyC, perforin-FITC, and G-CSF receptor (G-
SF-R)–biotin-SA-APC (Becton Dickinson, San
ose, CA). T cells were evaluated by ﬂow cytometry
fter staining with anti–CD4-CyC, anti–CD8-PE,
nd anti–TCR-FITC monoclonal antibodies.
emory and naive CD4 or CD8 T cells were
istinguished by positive co-staining with anti–
D45RO-APC or anti–CD45RA-CyC antibodies, re-
pectively. DCs were identiﬁed as lin/HLA-DR
ells and were classiﬁed as myeloid (CD11c/
D123) or plasmacytoid (CD11c/CD123). B
ells were identiﬁed by their expression of CD19 and
bsence of CD33. Natural killer (NK) and NK T cells
ere identiﬁed by their coexpression of CD3, CD8,
nd CD56. Lymphocyte values were expressed as an
bsolute number of cells per volume of whole blood
cells  104/mL). The cell concentration was calcu-
ated by the mononuclear cell count upon arrival to
he laboratory (cells/mL) multiplied by the percentage
f marker-positive cells.
mmune Cell Cytokine Assays
TCRCD8 and TCRCD8 cells were
lassiﬁed as Th/Tc1 and Th/Tc2 according to their
ytoplasmic staining with antibodies for various cyto-
ines, as previously described [28]. All cytokine assays
ere performed on low-density (1.077 g/mL) cells
solated by centrifugation on Ficoll-Hypaque (Amer-
ham, Uppsala, Sweden) and stimulated as described
elow. Cytokine and perforin monoclonal antibodies
sed were anti–IL-1-PE, anti–IL-6-PE, anti–IL-10-
PC, anti–IL-2-APC, anti–IFN--APC, anti–tumor
ecrosis factor--APC, anti–IL-4-APC, and anti–IL-
2-APC perforin-FITC (Becton Dickinson). Because
horbol myristate acetate (PMA)–ionomycin de-
reases CD4 expression, CD4 T cells were identiﬁed
s TCRCD8 cells. Mononuclear cells were
reated with PMA/ionomycin for stimulation of T-
nd NK-cell populations, with lipopolysaccharide
LPS) for activation of B cells and DCs, and with
FN- for stimulation of IL-10 and IL-12 secretion by
D19CD33 cells. All samples were incubated with
onensin to block cell glycoprotein export and en-
ance intracellular cytokine accumulation. Results p
26ere expressed as the stimulation index, which is the
atio of cytokine-positive cells in gated populations
eg, CD4 T cells) of stimulated cells compared with
nstimulated cells. The value of unstimulated cells
as set at a minimum of 1%.
FC Assays
CFC assays were performed by plating red blood
ell–depleted (Halifax) or CD34 cell–enriched
Vancouver) suspensions in methylcellulose-based
edium (Methocult; StemCell Technologies) con-
aining stem cell factor 50 ng/mL, granulocyte-mac-
ophage colony-stimulating factor 20 ng/mL, G-CSF
0 ng/mL, IL-3 20 ng/mL, IL-6 20 ng/mL, and
rythropoietin 3 U/mL to detect colony forming
nit–erythrocytes plus burst-forming unit–erythroids
lus colony forming unit–granulocyte-macrophages
lus colony forming unit–granulocytes, erythrocytes,
egakaryocytes, and macrophages (total 	 CFCs) by
sing standard procedures for colony enumeration
fter a 2-week incubation period [29].
TC-IC Assays
CD34 cell–enriched PB or BM cells were as-
ayed for LTC-ICs by plating aliquots of 5 104 cells
nto replicate 2.5-mL cultures containing preestab-
ished irradiated feeder layers of murine ﬁbroblasts
ngineered to secrete human G-CSF, IL-3, and stem
ell factor as previously described [29]. After 6 weeks,
ll cells in the cultures were harvested by trypsiniza-
ion, and appropriate aliquots were plated in CFC
ssays. The concentration of CFCs thus detected was
hen used to calculate the total number present in each
TC and, hence, the number of input LTC-ICs orig-
nally seeded into the culture, assuming that, on aver-
ge, 1 G-PB LTC-IC produces 25 CFCs and 1 BM
TC-IC produces 18 CFCs [29]. The number of
TC-ICs per 107 cells in the original low-density
-PB or G-BM population (and, hence, per liter of
ample) was then calculated, by knowing its content of
D34 cells and assuming that all LTC-ICs were
ow-density CD34 cells [29,30] and that there were
o losses in the various cell-isolation procedures.
enotransplant Assays of STRC Activity
A total of 105 CD34 cell–enriched human PB
nd BM cells were injected intravenously together
ith 106 irradiated (carrier) human BM cells into
ublethally irradiated (350 cGy) nonobese diabetic/
evere combined immunodeﬁciency (NOD/SCID)/
2-microglobulin–null mice as previously described
30]. Three weeks after transplantation, femoral BM
spirates were obtained [31]. After 8 weeks, mice were
illed, and all BM cells were isolated from their fe-
urs. Each BM sample obtained from the mice was
rocessed individually as follows: red blood cells were
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G-CSF Effects on Marrow and Peripheral Blood Cells
Bysed with ammonium chloride, and the cells were
tained with anti-human CD45, CD71, and pro-
idium iodide (Sigma Chemicals, St. Louis, MO) be-
ore ﬂow cytometric analysis by using gates set after
taining parallel aliquots of the same cells with ﬂuo-
ochrome-labeled isotype control antibodies as de-
cribed previously [31]. short-term repopulating cell–
yeloid (STRC-M) and short-term repopulating
ell–myeloid, lymphoid (STRC-ML) activity was ex-
ressed, respectively, as the percentages of cells in the
M of the mice 3 and 8 weeks after transplantation
hat were human CD45/71 per 107 cells in the
riginal low-density human G-PB or G-BM popula-
ions (and, hence, per liter of starting sample) by using
he same assumptions as for LTC-ICs. STRC assays
ere not performed on any of the pre–G-CSF (day 0)
B samples because of the small number of CD34
ells they contained and the expectation that these
ould not contain detectable numbers of STRCs [32].
herefore, to calculate -fold increases in these sam-
les, the day 0 value was assumed to be the minimum
etectable value.
tatistics
All data are shown as the mean
 SEM per liter of
tarting PB or BM sample or as a ratio relative to the
re–G-CSF (steady-state) value. In each case, values
ere calculated for each individual donor, and the
ean changes for the group were then plotted over
ime. Statistical signiﬁcance was assigned for P values
f .05, calculated by using the unpaired Student t
igure 1. Kinetics of G-CSF–induced changes in PB and BM
ellularity and CD34 cell numbers. TNCs (A) or CD34 cells (B)
er liter of PB (E) or BM aspirate (F) are shown relative to the
re–G-CSF value at different times after the initiation of a 4-day
chedule of G-CSF administration (G-CSF given on days 0, 1, 2,
nd 3). Values shown are derived from 10 healthy adults. The
umber of individuals was as follows: before G-CSF administration,
	 10; day 1, n 	 4; day 3, n 	 9; day 4, n 	 7; day 5, n 	 6; and
ays 9 to 12, n 	 10. The values are expressed as a ratio of the
ost–G-CSF measurement at each time point compared with the
re–G-CSF reference point. The SEM is present with each data
oint, but some of the error bars were smaller than the size of thepymbol.
B&MTest on mean values and the Fisher exact 2-tailed test
or discrete variables.
ESULTS
ffects on Total Cells and CD34 Cell
oncentrations in PB and BM
Healthy individuals given 4 daily injections of
-CSF showed the expected rapid transient in-
rease in the PB white blood cell count [33], which,
n this study, reached a maximum value after 3 to 4
ays (approximately 6-fold above baseline values;
 .05) and then returned to normal by days 9 to
2. The early increase in circulating white blood
ells was accompanied by a signiﬁcant (P  .05), but
ess marked, increase in the concentration of TNCs
per liter) in BM aspirate samples, peaking at ap-
roximately 3-fold above baseline on days 3 to 4, as
rst reported by Dicke et al. [23] and Isola et al.
24]. However, in contrast to the PB, the cellularity
f the BM aspirates was still high after the addi-
ional 5 to 9 days of follow-up (Figure 1A).
Changes in the concentration of CD34 cells in
oth PB and BM mirrored the changes seen in the
NC values. Peak concentrations were attained in
oth PB and BM by days 3 to 4, and these were then
ustained in the BM but returned to normal values
n the PB by days 9 to 12 (Figure 1B). However, the
agnitude of the G-CSF–stimulated increases in
D34 cell numbers in PB and BM samples was
uite different, with maximum increases of 26-fold
P  .05) and 1.5- to 1.7-fold (P  .05), respec-
ively. These ﬁndings conﬁrm those reported by
thers [23–25,34].
ffects on CFCs, LTC-ICs, and STRC Activity
As shown in Figure 2A, G-CSF treatment also
nduced the expected increases in the concentration of
FCs in the PB and BM aspirate samples with very
imilar kinetics to those seen for the total CD34
ells(peak increases of approximately 20-fold and
-fold seen on days 3 to 4 in PB and BM, respectively,
eturning to baseline by days 9 to 12). These results
re again similar to those documented in a number of
tudies [24,25,34–36]. Figure 2B shows that the same
attern of change in CFC numbers (per liter of PB or
M) was obtained from assays performed the same
ay in Halifax and the next day in Vancouver, despite
he 24-hour delay and differences in how the cells
ere processed before plating.
Figure 3 shows the changes seen in the concen-
rations of more primitive progenitors detected in
itro as LTC-ICs (Figure 3A and B) and in vivo as
TRCs. Both myeloid-restricted STRC activity (Fig-
re 3C and 3D; STRC-Ms, 3-week repopulation end
oint in NOD/SCID-2-microglobulin–null mice)
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6nd STRC activity with lymphoid and myeloid differ-
ntiation potential (Figure 3E and 3F; STRC-MLs, 6-
o 8-week repopulation end point in NOD/SCID-2-
icroglobulin–null mice) [23] were assessed. The ac-
ivity of all 3 of these primitive cell types increased
apidly, albeit variably, in PB and BM, again with
reater increases in the PB (peak increases of 700- to
000-fold) than in the BM (50- to 90-fold) on days 3
o 4. The increases in LTC-IC activity were also
omewhat larger than those reported previously
25,26,35,36], possibly because, at least in part, of the
se of different LTC-IC assay conditions, which de-
ect different progenitor subsets with different efﬁ-
iencies [29]. We also noted that, in contrast to the
ore sustained increases in CFCs and total CD34
ells (Figures 1 and 2), the increase in LTC-IC activ-
ty seen after 3 to 4 days was short-lived and, in both
B and BM samples, had consistently declined by
ay 5.
ffects on T and NK Cells
The increase in CD3/TCR T cells on day 5
ompared with pre–G-CSF values was also higher in
he PB than in the BM samples (2.2
 0.6 versus 0.9

.3; P 	 .10), although the absolute concentrations of
D4 and CD8 T cells on day 5 were actually
igher in the BM aspirates than in the PB samples
Figure 4A and 4B). The relative change in both
D4 and CD8 T cells (Figure 4B and 4D) was not
igniﬁcant. The greater numbers of CD3/TCR T
ells in the day 5 PB samples could be attributed
rimarily to increased numbers of CD8/TCR T
ells (Figure 4A; P 	 .07) that were CD45RO (data
ot shown; P 	 .05). No signiﬁcant changes were
etected in the concentrations of either NK or NK T
igure 2. Kinetics of G-CSF–induced changes in CFC numbers in
he PB and BM. A, Changes in the absolute number of CFCs per
iter of PB (E; data from Vancouver assays) or BM aspirate samples
F; data from Vancouver assays) from the same individuals as in
igure 1. The values are expressed as a ratio of the post–G-CSF
easurement at each time point compared with the pre–G-CSF
eference point. B, The same data expressed relative to the pre–G-
SF values (; CFC Halifax; PB data from Halifax assays).ells (data not shown). a
28No signiﬁcant changes were seen in the concen-
ration of T cells activated to produce IL-2, IL-4, or
umor necrosis factor- (data not shown). Signiﬁ-
antly increased proportions of IFN-CD8 T cells
nd CD8/TCR (primarily CD4) T cells were
een in the day 3 BM samples (Figure 4E and 4G; P	
03 and .02, respectively). However, evaluation of the
atio of the IFN-–producing CD8 (Figure 4F) and
D4 (Figure 4H) T cells revealed that, even though
here was a signiﬁcant increase in IFN-–producing
D4 and CD8 T cells in the BM, the difference
uickly disappeared between days 3 and 9. The con-
entration of IFN-–producing NK T cells (CD3/
D56) in the BM was also increased on day 5,
igure 3. Kinetics of G-CSF–induced changes in primitive progen-
tors in the PB and BM. A, Absolute number of LTC-ICs per liter
f PB (E) or BM aspirate samples (F) from a subset of the same
ndividuals as in Figure 1 (n 	 5; P  .05 only for PB on day 5). B,
ame data expressed relative to the pre–G-CSF values (P  .05 on
ays 3 and 4). C and E, Absolute STRC activity per liter of the same
B (E) or BM aspirate samples (F) (STRC-Ms: panel C, n	 5, P
05; STRC-MLs: panel E, n 	 5, P  .05). D and F, The same data
s in C and E, respectively, expressed relative to the pre–G-CSF
ctivity.
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G-CSF Effects on Marrow and Peripheral Blood Cells
BB&MTigure 5. G-CSF induces greater increases in the concentration of
cells and plasmacytoid DCs (pDCs) in the BM as compared with
he PB. Results for absolute (A) and relative (B) numbers of total
D19CD33 B cells in PB (E) and BM aspirate samples (solid
ymbols) are shown for the same samples analyzed in Figures 1 to 4.
igniﬁcant differences between PB and BM were seen on days 0 and
(*). DCs were deﬁned as lin/HLA-DR cells and were subclas-
iﬁed as myeloid (mDC) CD123/CD11c or pDC CD123/
D11c cells. The difference between BM and PB CD123 DCs
as signiﬁcant at both day 3 (P 	 .01) and day 5 (P 	 .02) and is
epresented by an asterisk. The number of individuals per time
eriod was as follows: before G-CSF administration, n 	 10; day 1,
	 4; day 3, n 	 9; day 5, n 	 6; and day 9, n 	 4. The values in
anels A, C, E, and G are expressed as the number of cells 
04/mL of whole blood; values in panels B, D, F, and H areigure 4. Effect of G-CSF treatment on T-cell populations. Shown
re the changes in the absolute (A and C) and relative (B and D)
umbers of TCRCD8 T cells (A and B) and CD4 T cells (C
nd D) measured on the same PB (E) and BM samples (F) as in
igure 1 (10 healthy donors). E to H, Corresponding results for the
FN-–producing CD8 and CD4 T cells detected after stimu-
ation with PMA/ionomycin. Differences between G-BM and G-PB
hat were signiﬁcant (P  .05) by a Student t test are identiﬁed with
n asterisk (*). The number of individuals per time period was as
ollows: before G-CSF administration, n 	 10; day 1, n 	 4; day 3,
	 9; day 5, n 	 6; and day 9, n 	 4. The values in panels A, C,
nd E are expressed as the number of cells  104/mL of whole
lood; values in panels B, D, F are expressed as the ratio of post–xpressed as the ratio of post–G-CSF to pre–G-CSF values.
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6lthough this increase was not signiﬁcant (P 	 .06;
ata not shown).
ffects on Accessory Cells
An increase in the concentration of
D19CD33 B cells in both the PB and BM was
een on day 3 (P 	 .05), which then rapidly declined,
lthough absolute levels of these cells remained higher
n the BM (Figure 5A). However, the B cells in the
M did not seem to be activated (ie, there was no
ncrease in IL-1 or IL-6 production). The relative
ncrease in B cells (Figure 5B) was greater in the PB
fter G-CSF because of the low concentration of B
ells in pre–G-CSF PB.
By day 5, G-CSF treatment produced a signiﬁ-
antly larger population of plasmacytoid (lin/HLA-
R/CD123) DCs (Figure 5C and 5D) in the BM
han in the PB (8.8 
 2.7 versus 1.3 
 0.5  104/mL;
	 .02), whereas the levels of myeloid (lin/HLA-
R/CD11c) DCs (Figure 5E and 5F) became sim-
lar (4.5 
 1.3 versus 3.1 
 2.3; P 	 .63), despite
igniﬁcantly higher concentrations of both CD11c
nd CD123DCs in steady-state BM samples (Figure
C and 5E). As seen for B cells, the relative increase in
oth plasmacytoid DCs (Figure 5F) and myeloid DCs
Figure 5D) was less striking in BM because of the
igher concentration of these populations in steady-
tate BM. The number of IL-6–producing CD33
onocytes was also increased in the PB on days 3 and
(data not shown; P 	 .05).
ffects on G-CSF-R T and B Cells
G-CSF-Rs are expressed on both T cells and B
ells, and G-CSF-R T cells can be induced to in-
rease expression of GATA-3 [18]. We hypothesized
hat the greater effect of G-CSF treatment on B cells
n BM versus PB (Figure 4A) could be due to (1) a
elective expansion and retention of G-CSF-R B
ells in the BM, (2) a decrease in perforin-containing
or NK cells needed to inhibit B-cell expansion [37],
3) an increase in immature or naive B cells [38], or (4)
skewed effect of G-CSF on regulatory CD4CD25
cells. We therefore evaluated the samples from the
ast 4 volunteers for potential changes in these cell
able 1. Evaluation of Cell Populations in G-CSF–Primed Bone Marr
Cell Markers
Before GSF ( 104)
PB BM P Value
D4CD25TCR/ 12.6  6.5 13.9  8.7 .90 7
CR/ 5.7  2.8 24.9  12.8 .20 35
cells perforin
(CD3/CD56) 18.3  7.2 42.0  16.3 .20 12
K cells perforin
(CD3/CD56) 12.4  4.0 50.7  21.5 .10 20opulations (Table 1). No difference was found in the o
30umbers of CD4/CD25 T cells present in the BM
s compared with the PB after G-CSF. There was,
owever, a trend toward expansion of G-CSF-R T
ells in the day 5 BM aspirates. There was also a large
ecrease in perforin-expressing T and NK cells in the
ay 5 BM samples that approached the levels seen in
he PB. In the same samples, naive immunoglobulin
/G-CSF-R B cells were present at higher levels in
he BM (Figure 5). However, none of these differ-
nces was signiﬁcant, likely because of the small num-
ers of samples compared (Figure 6).
ISCUSSION
In this study, we describe the parallel kinetics of
-CSF–induced effects on the BM and PB content of
everal progenitor cell populations thought to con-
ribute to the early regeneration of hematopoiesis af-
er transplantation. These include the ﬁrst measure-
ents of 2 types of human cells with short-term
epopulating activity in engrafted immunodeﬁcient
ice [22,39,40], in addition to the total CD34 cell
opulation, CFCs, and LTC-ICs, deﬁned with a
PB (n 	 4)
3 days ( 104) 5 days ( 104)
BM P Value PB BM P Value
8 12.1  9.3 .50 8.0  4.8 8.1  4.9 1.0
57.0  14 .30 58.8  53.8 30.3  9.4 .60
0 25.1  12 .40 17.6  17.6 18.3  9.6 1.0
9 30.0  3.9 .20 19.6  8.5 17.9  7.9 .90
igure 6. G-CSF-R expression on B cells in G-CSF–stimulated
M versus PB. Immunophenotyping was performed by 4-color ﬂow
ytometry after staining for CD19, CD33, immunoglobulin D, and
-CSF-R 5 days after the initiation of G-CSF treatment. B cells
ere identiﬁed as CD19/CD33 and were further evaluated for
xpression of immunoglobulin D, G-CSF-R, or both. The concen-
ration of cells ( 104/mL) is expressed in the ﬁgure. The numberow and
PB
.8  3.
.3  15
.6  2.
.3  4.f individuals was 4.
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G-CSF Effects on Marrow and Peripheral Blood Cells
B-week CFC readout [29]. Population size compari-
ons were made for ﬁxed volumes of BM aspirate or
B samples by using standardized culture reagents and
etection criteria. To minimize variability in the ex-
ent of PB contamination of BM aspirates, all BM
spirates were obtained by 2 individuals, who used a
tandardized technique. Average changes over time
ere then assessed after ﬁrst normalizing the data for
ach sample to the corresponding pre–G-CSF value
or the same individual.
All hematopoietic cell types evaluated had similar
apid kinetics of expansion, usually reaching a peak on
ay 3 or 4 after the 4-day G-CSF treatment protocol
as started. However, the magnitude of the increases
btained and their durability varied for the various
ypes of progenitors. In general, the magnitude of the
xpansions was approximately 10-fold higher in PB
han in BM, but it varied over a wide range, depending
n the cell type being assessed. Considerable variabil-
ty between individual donor responses was also seen.
s anticipated from previous measurements of
hanges in CD34 cells, CFCs and LTC-ICs
25,35,36]—the more primitive cell populations—
howed the greatest G-CSF–induced effects. Thus,
lthough CFC numbers in the BM showed very little
hange, there was an approximately 50-fold increase
n LTC-IC activity and an approximately 90-fold in-
rease in STRC activity. Similarly, in the PB, the
ncreases in LTC-IC and STRC activity were 40- to
00-fold higher than the increases in CFC numbers.
owever, these effects of G-CSF on circulating
TRC activity need to be interpreted with caution
ecause they are based on the assumption that before
-CSF administration, STRC numbers were at or
elow the detection limit. It is also important to note
hat, despite the large expansion seen in the numbers
f circulating primitive progenitors, these still re-
ained lower than in the BM, except in the case of the
TC-ICs, where PB values up to 35 times those
easured in the BM were seen.
In addition to differences in the extent to which
arious progenitor populations were expanded, there
ere also differences in the period over which these
xpansions were sustained. The more primitive pro-
enitors showed the shortest-lived responses to the 4
ays of G-CSF administration, as evidenced by a de-
line in progenitor activity in both PB and BM im-
ediately after the peak value reached on the last day
f G-CSF treatment or a day later. These ﬁndings
uggest that the regenerative activity of an allograft
arvest could be signiﬁcantly affected by the timing of
he BM or PB cell collection after the cessation of
-CSF administration, with an optimal collection
ime being the day after completion of a 3- or 4-day
ourse.
A small randomized trial comparing G-PB and
-BM allografts has demonstrated that transplanta- t
B&MTion of G-PB is associated with a much higher fre-
uency of chronic GVHD compared with G-BM [14].
uch an observation suggests differences in the in-
used immune populations in G-BM compared with
-PB and requires conﬁrmation by a larger clinical
rial. In this study, we identiﬁed 2 cell populations (B
ells and plasmacytoid DCs) that were increased to
uch higher levels in G-BM compared with G-PB. B
ells seem to play a role in the development of chronic
VHD as producers of both autoreactive immuno-
lobulin and APCs. It is interesting to note that B cells
ave been shown to play a role in the induction of
VHD in murine models [41], and recent human
tudies have demonstrated that treatment with ritux-
mab, a monoclonal antibody against CD20 cells, can
nﬂuence the onset of GVHD [42] and can be used as
herapy for GVHD [43]. Similarly, B-cell production
f autoreactive immunoglobulins and T cell/B cell
nteractions play an important role in GVHD [44,45].
e hypothesized that the expanded B-cell population
ound in G-BM may be produced either by a loss of
ells with negative regulatory activities—eg, perforin-
ontaining cytolytic (NK and/or CD8) T-cell pop-
lations—or by direct stimulatory effects of G-CSF
n B cells with expansion of G-CSF-R B cells
37,38]. We therefore evaluated the type of B-cell
opulations that were expanded in the G-BM samples
btained from the last 4 donors. These analyses failed
o detect any differences in the number of perforin-
ositive T or NK cells, although the small number of
ndividuals evaluated likely precluded a deﬁnitive con-
lusion. Our ﬁndings also failed to support the hy-
othesis that there was direct effect of G-CSF on B
ells that resulted in a selective expansion of
-CSF-R B cells in G-BM. In contrast, an increased
oncentration of immunoglobulin D B cells was
oted in the G-BM samples, suggesting a shift in favor
f naive B-cell expansion in G-BM. In a transplant
etting, this might, in turn, inhibit T-cell activation
nd promote the induction of tolerance [46,47]. All 3
echanisms of B-cell function—including presenta-
ion of antigen to T cells, antibody production, and
ytokine production—have been shown to play an
mportant role in the development of chronic GVHD
41,44,48].
Plasmacytoid DCs were present in greater num-
ers in the G-BM samples than in the G-PB samples.
e observed an overall expansion of both myeloid
CD11c) and plasmacytoid (CD123) subpopula-
ions of DCs but noted a shift toward a predominance
f plasmacytoid DCs in G-BM. Plasmacytoid DCs
ave been associated with the presence of chronic
VHD in humans and are of donor origin [49]. There
s good evidence that decreased chronic GVHD is
ssociated with a predominance of plasmacytoid DCs;
his is supported by the fact that extracorporeal pho-
opheresis results in a shift from myeloid DCs to
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6lasmacytoid DCs [50]. Others have shown that a
ower incidence of chronic GVHD and a higher leu-
emia relapse rate were associated with higher num-
ers of infused plasmacytoid DCs. This may be due to
he ability of plasmacytoid DCs to induce a shift to a
-helper type 2/Tc2 response after BMT [51]. Some
f the conﬂicting results regarding the role of DCs in
hronic GVHD may reﬂect whether the DCs are of
onor or host origin. Unlike in acute GVHD, in
hich host DCs seem to be a major antigen presenting
ell, both donor plasmacytoid DCs [49] and host DCs
52] have been associated with increased chronic
VHD in humans. These cells respond differently to
ctivation factors such as LPS and CpG oligode-
xynucleotides [53], with subsequent IFN production
54], consistent with their playing a different role in
ctivating other populations that contribute to
VHD. The response to TLR9 stimulation by CpG
ligodeoxynucleotides has been associated with the
evelopment of GVHD [28]. The decreased rate of
esponse by cord blood DCs to CpG stimulation [55]
nd the profound inhibition of B-cell responses in
VHD to CpG stimulation by 4-aminoquinolines,
uch as hydroxychloroquine [28,41], highlight this po-
ential mechanism in GVHD. Moreover, signiﬁcant
nteraction exists between B-cell and plasmacytoid
C populations in altering the immune response [56].
We were not able to demonstrate any signiﬁcant
ifferences in cytokine production after mitogen stim-
lation (PMA/ionomycin for T cells and LPS for B
ells). We did not evaluate T- or B-cell responses to
ither alloantigens or pathogens. It is possible that
ifferences between G-PB and G-BM T cells may
ave been observed in such responses.
In conclusion, the results presented here describe
ifferences in subsets of cells within the PB and BM
ompartments in response to G-CSF. Although these
ifferences may explain site-speciﬁc effects of G-CSF
n vivo, our study was limited by being solely descrip-
ive in nature. Therefore, it does not afford a deﬁni-
ive explanation for the differences in hematologic
ecovery and GVHD seen with different allograft
ources. Our results may also have implications for the
iming of leukapheresis harvests from G-CSF–treated
ealthy donors. However, because of how the aphere-
is product is collected, both the relative and absolute
umbers of all the cell types we have measured would
ikely be different from those documented here for
hole PB. Similarly, the G-BM results in this study
ere derived from a ﬁrst aspiration that would have
een minimally diluted with PB. A BM harvest sufﬁ-
ient for a transplant represents a more diluted prod-
ct containing more PB cells. The results from these
tudies, although representing biological differences
etween G-CSF–stimulated marrow and PB, cannot
e directly correlated to the infused products collected
rom G-CSF–stimulated donors. Further analyses
32omparing the composition of harvested G-BM and
pheresed G-PB with clinical hematologic recovery
nd other clinical outcome parameters—including
VHD—will be needed to determine the ultimate
redictive utility of the type of BM and PB assess-
ents reported here. Such studies are planned as part
f a large Canadian Bone Marrow Transplant Group
tudy comparing G-BM with G-PB.
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